kabutan

Kringle Pharma,Inc.(4884) Summary

4884
TSE Growth
Kringle Pharma,Inc.
484
JPY
+5
(+1.04%)
Apr 28, 3:30 pm JST
3.04
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
476
Apr 28, 10:13 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.01
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
485 JPY 3.04 USD
Previous Close Apr 27
479 JPY 3.00 USD
High Apr 28, 9:08 am
499 JPY 3.13 USD
Low Apr 28, 1:53 pm
479 JPY 3.00 USD
Volume
455,000
Trading Value
0.22B JPY 1.40M USD
VWAP
489.68 JPY 3.08 USD
Minimum Trading Value
48,400 JPY 304 USD
Market Cap
3.58B JPY 0.02B USD
Number of Trades
871
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
Slightly High
1-Year Average
505
1-Year High Apr 2, 2026
15,888
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 1,754,000
Apr 17, 2026 0 1,472,500
Apr 10, 2026 0 1,627,200
Apr 3, 2026 10,500 1,416,800 134.93
Mar 27, 2026 0 867,800
Company Profile
Kringle Pharma, Inc. is engaged in the research and development of therapeutic drugs for intractable diseases using HGF protein.
Sector
Pharmaceuticals
Kringle Pharma, Inc. is engaged in the research and development of therapeutic drugs for intractable diseases using HGF protein. The company is currently conducting clinical trials for acute spinal cord injury, ALS, vocal cord scarring, and acute kidney injury. For acute spinal cord injury, a Phase III trial is in progress, aiming for a marketing authorization application. For ALS, the company is analyzing the results of a Phase II trial. A Phase III trial is underway for vocal cord scarring, while plans for the next phase of trials for acute kidney injury are being developed. Leveraging the neuroprotective and anti-fibrotic effects of HGF, Kringle Pharma aims to expand its applications to multiple intractable diseases. The company is also strengthening its new pipeline through collaborative research with universities and other companies.